TL;DR

Stem cell therapy for joints and the spine typically uses bone marrow aspirate concentrate, a preparation drawn from the patient's own bone marrow that is rich in mesenchymal stem cells and growth factors. It is injected under imaging guidance into joints, tendons, or spinal structures to support tissue repair. Not every patient is a candidate, and a thorough evaluation is required before any procedure.

If you’re comparing treatments, start with the clinic’s overview of regenerative medicine options before discussing your options with a clinician.

Key takeaways

• Bone marrow aspirate concentrate, or BMAC, is the most common cell-based regenerative treatment used in musculoskeletal and spine care in the US.
• Patient selection matters more than the technology: a thorough evaluation of the diagnosis, imaging, and prior treatment history is essential before any regenerative procedure.
• Underlying mechanical imbalances should be identified and addressed alongside any biologic treatment to support lasting results.

What Is Stem Cell Therapy in the Context of Musculoskeletal Care?

In musculoskeletal medicine, stem cell therapy refers to procedures that use the body's own regenerative cells, typically drawn from bone marrow or adipose tissue, to support tissue repair in joints, tendons, or spinal structures.

The phrase "stem cell therapy" covers a wide range of procedures, and that range can make it confusing for patients trying to research their options. In the context of spine and joint care, the term most often refers to the use of mesenchymal stem cells, which are adult progenitor cells that can differentiate into bone, cartilage, and connective tissue. The most common clinical source on Long Island and across the US is bone marrow aspirate concentrate, or BMAC. In a BMAC procedure, a physician draws a small amount of bone marrow, usually from the back of the pelvis, concentrates it using a centrifuge, and injects the resulting preparation into the target area. The goal is to deliver a concentrated population of cells and growth factors directly to tissue that has limited natural blood supply and heals slowly on its own. Tendons, cartilage, and spinal discs fall into this category. Cell-based regenerative treatments are distinct from platelet-rich plasma, or PRP, which is drawn from peripheral blood and works primarily through growth factor delivery rather than cellular engraftment. Understanding that distinction helps patients have a more informed conversation with their physician about which approach, if any, fits their situation.

How Bone Marrow Aspirate Concentrate Works

BMAC delivers a concentrated mix of mesenchymal stem cells, growth factors, and anti-inflammatory cytokines to an injured area, where they may support the local repair environment.

When tissue is injured, the body initiates a repair sequence that depends on cell signaling, inflammation control, and the arrival of progenitor cells. In structures with poor blood supply, this sequence is slow and sometimes incomplete. BMAC is designed to accelerate that sequence by introducing a concentrated biologic preparation directly to the affected site. Research published in peer-reviewed journals, including work indexed in PubMed, has examined BMAC for knee osteoarthritis, rotator cuff tears, and lumbar disc degeneration. Results across studies are variable, and larger randomized controlled trials are still needed to establish definitive protocols. What the existing evidence does support is that the procedure is generally well tolerated, carries a low risk of adverse reaction because the material comes from the patient's own body, and may reduce pain and improve function in selected patients. Precision in delivery is important. Injecting into the right anatomical location, confirmed under imaging guidance, increases the likelihood that the biologic material reaches the intended tissue. At Spine and Sports Rehab NY, injections are performed under ultrasound or fluoroscopic guidance so the clinician can confirm placement in real time.

Which Conditions Are Researchers Studying Cell-Based Treatments For?

Current research is most active in knee osteoarthritis, rotator cuff tears, hip labral pathology, and degenerative disc disease of the lumbar spine.

Patients who ask about stem cell therapy for joints and the spine are often dealing with one of several overlapping conditions. Knee osteoarthritis is the most researched application, with multiple clinical trials examining whether BMAC can reduce cartilage breakdown and relieve pain compared with corticosteroid injections or hyaluronic acid. The shoulder is another area of active study, particularly partial-thickness rotator cuff tears where surgery carries meaningful downtime and rehabilitation demands. For the spine, researchers are exploring whether BMAC or other cell-based preparations injected into degenerative discs can slow the degenerative process or reduce pain arising from the disc itself. This is earlier-stage research compared with joint applications, and it is important for patients to understand that while early findings are encouraging, these treatments are not yet a proven standard of care for all spinal indications. Results vary depending on the degree of degeneration, patient age, activity level, and how long the condition has been present. A physician who is honest about that variability is one you can trust.

Why Candidacy Matters More Than the Treatment Itself

Whether a patient is likely to benefit from cell-based therapy depends far more on a thorough diagnosis and candidacy evaluation than on the treatment technology itself.

Dr. Jordan Sudberg, MD, a physiatrist and pain management specialist at Spine and Sports Rehab NY on Long Island, addresses this directly: "Regenerative medicine should not be viewed as a one-size-fits-all solution. The important question is whether a particular regenerative treatment is appropriate for the individual patient and the specific tissue or condition being treated." That framing is worth sitting with, because the marketing around stem cell therapy can create the impression that it works for nearly anyone with joint or spine pain. In practice, a patient with severe, end-stage osteoarthritis where cartilage is essentially absent may not respond the same way as a patient with moderate, early-to-mid-stage degeneration and an otherwise favorable healing environment. Similarly, a patient whose pain is driven primarily by a mechanical issue, such as a leg length discrepancy or significant muscle imbalance, may not achieve lasting relief from any injection alone. Dr. Sudberg expands on this point: "Regenerative medicine isn't a one-size-fits-all miracle fix; without correcting underlying mechanical imbalances and structural stressors first, biologic treatments won't achieve lasting tissue repair." This is why candidacy evaluation, not the injection itself, is the most important step in the process.

What a Proper Evaluation Looks Like Before Any Injection

A thorough evaluation includes a detailed history, physical examination, diagnostic imaging review, and a discussion of prior treatments before any regenerative procedure is recommended.

Patients who have seen multiple providers before arriving at a regenerative medicine consultation often report that previous appointments felt rushed. A proper candidacy evaluation for cell-based treatment should take enough time to understand not only the diagnosis but also the story behind it. That means reviewing prior imaging, discussing what has and has not worked, performing a hands-on physical exam, and in some cases ordering updated imaging to see current tissue status. At Spine and Sports Rehab NY, the evaluation process is structured to answer a specific question: is this patient's pain coming from a source that biologic treatment could plausibly address, and is there evidence that the healing environment is adequate to respond? That process may also involve a discussion of complementary steps such as physical therapy, activity modification, or exercise programming, because those factors affect how well any regenerative treatment performs. Patients should also know that a qualified clinician will tell them if they are not a good candidate. That honesty protects patients from spending time and money on a treatment unlikely to help them.

Is Stem Cell Therapy Right for You?

Only a qualified physician who has reviewed your history, imaging, and physical exam can answer that question. This article provides general information, not personal medical advice.

If you have been living with persistent joint or spine pain and have already tried rest, physical therapy, or cortisol injections without lasting relief, a conversation about cell-based regenerative options may be worth having. The range of conditions that may respond to BMAC or similar treatments is meaningful, but so is the range of conditions that require a different path. What the research and clinical experience consistently show is that patient selection, precise injection technique, and addressing the broader mechanical picture all influence outcomes. This article is intended to give you a foundation for that conversation, not to substitute for one. Please consult a qualified clinician about your own situation before drawing conclusions about whether any regenerative treatment is appropriate for you. If you want to learn more about the broader landscape of cell-based and other regenerative options, the overview of regenerative medicine services at Spine and Sports Rehab NY is a useful next step.

Frequently asked questions

What is bone marrow aspirate concentrate and how is it used for joint pain?

Bone marrow aspirate concentrate, or BMAC, is a preparation drawn from the patient's own bone marrow that contains mesenchymal stem cells, growth factors, and anti-inflammatory cytokines. It is injected under imaging guidance into joints, tendons, or spinal structures to support the local repair environment. It is most studied for knee osteoarthritis and rotator cuff pathology.

Is stem cell therapy for the spine FDA approved?

The FDA regulates cell-based therapies and has issued guidance distinguishing minimally manipulated autologous preparations, such as BMAC, from more heavily processed products. BMAC falls within a regulatory framework that permits its use in clinical practice, but patients should discuss the specific regulatory status and evidence base with their physician.

How is stem cell therapy different from PRP?

Platelet-rich plasma, or PRP, is drawn from peripheral blood and delivers a concentration of growth factors and platelets to support healing. Stem cell therapy using BMAC delivers mesenchymal stem cells along with growth factors, targeting tissue repair through a cellular mechanism. Both are biologic, autologous treatments, but they work through different pathways and may be suited to different conditions.

Who is not a good candidate for stem cell therapy in joints or the spine?

Patients with end-stage joint degeneration, active infection, certain blood disorders, or significant untreated mechanical imbalances may not be good candidates. A physician-led evaluation that includes imaging and a thorough history is the only way to determine candidacy for an individual patient.